Diagnostic Test: Blood Test

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
48Primary antiphospholipid syndrome2
51Scleroderma1
75Cushing disease1
IDDisease name (Link within this page)Number of trials
298Hereditary pancreatitis2
300IgG4-related disease1

48. Primary antiphospholipid syndrome


Clinical trials : 96 / Drugs : 112 - (DrugBank : 22) / Drug target genes : 20 - Drug target pathways : 138 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

51. Scleroderma


Clinical trials : 740 / Drugs : 813 - (DrugBank : 165) / Drug target genes : 140 - Drug target pathways : 231 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

75. Cushing disease


Clinical trials : 231 / Drugs : 224 - (DrugBank : 47) / Drug target genes : 63 - Drug target pathways : 145 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

298. Hereditary pancreatitis


Clinical trials : 126 / Drugs : 210 - (DrugBank : 59) / Drug target genes : 65 - Drug target pathways : 161 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

300. IgG4-related disease


Clinical trials : 81 / Drugs : 90 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 152 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries